LYPD3, His, Mouse
LYPD3, His, Mouse

The purity of LYPD3, His, Mouse is greater than 95% as determined by SEC-HPLC.

LYPD3, His, Mouse

LYPD3, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

LYPD3, His, Mouse

Aberrant expression of LYPD3 plays an oncogenic role in several types of cancer.LYPD3 was able to be regulated by the methylation in LYPD3 promoter region, which was positively associated with the overall survival. Furthermore, we explored the related pathways through which LYPD3 affects the pathogenesis and prognosis of LUAD by gene set enrichment analysis, and found that LYPD3 might affect the clinical manifestations of LUAD by regulating the P53 signaling pathway.
Z06257
¥69,021.00

Ask us a question
Product Introduction
Species Mouse
Protein Construction
LYPD3 (Leu33-His287)_x000D_
Accession # Q91YK8		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 27.6 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • LYPD3, His, Mouse
    • LYPD3, His, Mouse

    The purity of LYPD3, His, Mouse is greater than 95% as determined by SEC-HPLC.

  • LYPD3, His, Mouse
    • LYPD3, His, Mouse

    LYPD3, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Aberrant expression of LYPD3 plays an oncogenic role in several types of cancer.LYPD3 was able to be regulated by the methylation in LYPD3 promoter region, which was positively associated with the overall survival. Furthermore, we explored the related pathways through which LYPD3 affects the pathogenesis and prognosis of LUAD by gene set enrichment analysis, and found that LYPD3 might affect the clinical manifestations of LUAD by regulating the P53 signaling pathway.
Synonyms MIG-C4; LYPD3; C4.4A; LY6/PLAUR domain containing 3

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.